Beilin Le
Direktor/Vorstandsmitglied bei Mirxes Holding Co., Ltd.
Profil
Beilin Le currently works at Mirxes Holding Co., Ltd., as Non-Executive Director from 2021.
Dr. Le received his doctorate degree in 2015 from National University of Singapore and undergraduate degree in 2011 from Fudan University.
Aktive Positionen von Beilin Le
| Unternehmen | Position | Beginn |
|---|---|---|
Mirxes Holding Co., Ltd.
 Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Direktor/Vorstandsmitglied | 01.01.2021 |
Ausbildung von Beilin Le
| Fudan University | Undergraduate Degree |
| National University of Singapore | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Mirxes Holding Co., Ltd.
Mirxes Holding Co., Ltd. Financial ConglomeratesFinance Mirxes Holding Co., Ltd. operates as an investment holding company. It is engaged in developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Infectious Diseases and Early Detection and Precision Multi-Omics. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits and provision of infectious disease clinical testing. The Early Detection and Precision Multi-Omics involves in Development, manufacture, supply of diagnostic & life sciences products, and provision of research profiling, clinical testing and clinical services. The company was founded by Too Heng Phon, Zhou Lihan and Zou Ruiyang in 2014 and is headquartered in Singapore. | Finance |
